Chimeron Bio is pioneering the next frontier in genetic medicine through breakthrough MultiPlex delivery technology. We are transforming the treatment of cancer and beyond by enabling complex In Vivo CAR-T therapies directly in patients – combining the precision of genetic medicine with the accessibility of traditional biologics.
Founded on revolutionary advances in self-amplifying RNA and targeted delivery, Chimeron addresses fundamental barriers that have limited the potential of genetic therapies, positioning our technology at the center of a rapidly expanding market validated by over $3 billion in recent pharmaceutical acquisitions.
Scientific Foundation
Our breakthrough emerged from addressing a fundamental challenge in genetic medicine: How do you deliver complex, multi-gene therapeutic programs directly in patients with precise control and optimal durability? Through years of innovative research combining advanced RNA engineering with targeted delivery systems, we developed the first approach capable of MultiPlex In Vivo CAR-T – opening new possibilities for therapeutic approaches previously considered impossible.
Partnership Philosophy
We believe the greatest therapeutic impact comes through collaboration with industry leaders who share our vision of making advanced genetic therapies accessible worldwide. Our approach designed for partnership – offering flexible licensing models, co-development opportunities, and manufacturing collaborations tailored to advance breakthrough treatments across multiple disease areas.
Strategically Located in Philadelphia
We operate at the heart of the East Coast biotech corridor with direct access to world-class research institutions, advanced manufacturing infrastructure, and global pharmaceutical partners.
